|
|
Line 44: |
Line 44: |
| * [[Subacute thyroiditis]] | | * [[Subacute thyroiditis]] |
| * Hyperthyroidosim due to ectopic thyroid tissue | | * Hyperthyroidosim due to ectopic thyroid tissue |
|
| |
| ==Differential diagnosis==
| |
|
| |
|
| |
| {| style="border: 0px; font-size: 90%; margin: 3px;" align=center
| |
| ! style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 | {{fontcolor|#FFFFFF|Cause of thyrotoxicosis}}
| |
| ! style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 | {{fontcolor|#FFFFFF|TSH receptor Antibodies}}
| |
| ! style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 | {{fontcolor|#FFFFFF|Thyroid US}}
| |
| ! style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 | {{fontcolor|#FFFFFF|Color flow Doppler}}
| |
| ! style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 | {{fontcolor|#FFFFFF|Radioactive iodine uptake/Scan}}
| |
| ! style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 | {{fontcolor|#FFFFFF|Other features}}
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Graves' disease}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | +
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Hypoechoic pattern
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Ophthalmopathy, dermopathy, acropachy
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Toxic nodular goiter}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Multiple nodules
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Hot nodules at thyroid scan
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Toxic adenoma}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Single nodule
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Hot nodule
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Subacute thyroiditis}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Heterogeneous hypoechoic areas
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Neck pain, fever, and<br> elevated inflammatory index
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Painless thyroiditis}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Hypoechoic pattern
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Amiodarone induced thyroiditis-Type 1}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Diffuse or nodular goiter
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓/Normal/↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓ but higher than in Type 2
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | High urinary iodine
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Amiodarone induced thyroiditis-Type 2}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Normal
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Absent
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓/absent
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | High urinary iodine
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Central hyperthyroidism}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Diffuse or nodular goiter
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Normal/↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Inappropriately normal or high TSH
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Trophoblastic disease}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Diffuse or nodular goiter
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Normal/↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↑
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Factitious thyrotoxicosis}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Variable
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓ serum thyroglobulin
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=1 colspan=1 |{{fontcolor|#FFFFFF|Struma ovarii}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | -
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Variable
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | ↓
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Abdominal RAIU
| |
| |}
| |
|
| |
|
| |
| {| style="border: 0px; font-size: 90%; margin: 3px;" align=center
| |
| ! colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Disease}}
| |
| ! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Findings}}
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=5 colspan=1 |{{fontcolor|#FFFFFF|Thyroiditis}}
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Direct chemical toxicity with inflammation}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | [[Amiodarone]], [[sunitinib]], [[pazopanib]], [[axitinib]], and other [[tyrosine kinase inhibitors]] may also be associated with a destructive [[thyroiditis]].<ref name="pmid2258582">{{cite journal |vauthors=Lambert M, Unger J, De Nayer P, Brohet C, Gangji D |title=Amiodarone-induced thyrotoxicosis suggestive of thyroid damage |journal=J. Endocrinol. Invest. |volume=13 |issue=6 |pages=527–30 |year=1990 |pmid=2258582 |doi= |url=}}</ref><ref name="pmid24282820">{{cite journal |vauthors=Ahmadieh H, Salti I |title=Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment |journal=Biomed Res Int |volume=2013 |issue= |pages=725410 |year=2013 |pmid=24282820 |pmc=3824811 |doi=10.1155/2013/725410 |url=}}</ref>
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Radiation thyroiditis}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Patients treated with [[radioiodine]] may develop thyroid pain and tenderness 5 to 10 days later, due to radiation-induced injury and necrosis of thyroid follicular cells and associated [[inflammation]].
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Drugs that interfere with the immune system}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | [[Interferon alfa-2a clinical pharmacology|Interferon-alfa]] is a well known cause of thyroid abnormality. It mostly leads to the development of de novo antithyroid [[antibodies]].<ref name="pmid8351956">{{cite journal |vauthors=Vialettes B, Guillerand MA, Viens P, Stoppa AM, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D |title=Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies |journal=Acta Endocrinol. |volume=129 |issue=1 |pages=31–8 |year=1993 |pmid=8351956 |doi= |url=}}</ref>
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Lithium}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Patients treated with [[lithium]] are at a high risk of developing painless thyroiditis and Graves' disease.
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Palpation thyroiditis}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Manipulation of the thyroid gland during thyroid [[biopsy]] or neck surgery and vigorous palpation during physical examination may cause transient [[hyperthyroidism]].
| |
| |-
| |
| | style="background: #4479BA; padding: 5px 5px;" rowspan=4 colspan=1 |{{fontcolor|#FFFFFF|Exogenous and ectopic hyperthyroidism }}
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Factitious ingestion of thyroid hormone}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |The diagnosis is based upon the clinical features, laboratory findings, and 24-hour radioiodine uptake.<ref name="pmid2666114">{{cite journal |vauthors=Cohen JH, Ingbar SH, Braverman LE |title=Thyrotoxicosis due to ingestion of excess thyroid hormone |journal=Endocr. Rev. |volume=10 |issue=2 |pages=113–24 |year=1989 |pmid=2666114 |doi=10.1210/edrv-10-2-113 |url=}}</ref>
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Acute hyperthyroidism from a levothyroxine overdose}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |The diagnosis is based upon the clinical features, laboratory findings, and 24-hour radioiodine uptake.<ref name="pmid23067331">{{cite journal |vauthors=Jha S, Waghdhare S, Reddi R, Bhattacharya P |title=Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis |journal=Thyroid |volume=22 |issue=12 |pages=1283–6 |year=2012 |pmid=23067331 |doi=10.1089/thy.2011.0353 |url=}}</ref>
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Struma ovarii}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Functioning thyroid tissue is present in an [[ovarian neoplasm]].
| |
| |-
| |
| | style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Functional thyroid cancer metastases}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Large bony [[metastases]] from widely metastatic [[follicular thyroid cancer]] cause symptomatic hyperthyroidism.
| |
| |-
| |
| | colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Hashitoxicosis }}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |It is an autoimmune thyroid disease that initially presents with hyperthyroidism and a high radioiodine uptake caused by TSH-receptor antibodies similar to Graves' disease. It is then followed by the development of hypothyroidism due to the infiltration of thyroid gland with [[Lymphocyte|lymphocytes]] and the resultant autoimmune-mediated destruction of thyroid tissue, similar to chronic lymphocytic thyroiditis.<ref name="pmid5171000">{{cite journal |vauthors=Fatourechi V, McConahey WM, Woolner LB |title=Hyperthyroidism associated with histologic Hashimoto's thyroiditis |journal=Mayo Clin. Proc. |volume=46 |issue=10 |pages=682–9 |year=1971 |pmid=5171000 |doi= |url=}}</ref>
| |
| |-
| |
| | colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Toxic adenoma and toxic multinodular goiter}}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Toxic adenoma and [[toxic multinodular goiter]] are results of focal/diffuse [[hyperplasia]] of thyroid follicular cells independent of TSH regulation. Findings of single or multiple [[nodules]] are seen on physical examination or thyroid scan.<ref name="pmid2040867">{{cite journal |vauthors=Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G |title=High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland |journal=J. Intern. Med. |volume=229 |issue=5 |pages=415–20 |year=1991 |pmid=2040867 |doi= |url=}}</ref>
| |
| |-
| |
| | colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Iodine-induced hyperthyroidism }}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |It is uncommon but can develop after an iodine load, such as administration of contrast agents used for angiography or computed tomography (CT), or iodine-rich drugs such as [[amiodarone]].
| |
| |-
| |
| | colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Trophoblastic disease and germ cell tumors }}
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |[[Thyroid-stimulating hormone]] and [[HCG]] have a common alpha-subunit and a beta-subunit with considerable homology. As a result, [[HCG]] has weak thyroid-stimulating activity and high titer HCG may mimic hyperthyroidism.<ref name="pmid19605510">{{cite journal |vauthors=Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA |title=Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors |journal=Ann. Oncol. |volume=21 |issue=1 |pages=104–8 |year=2010 |pmid=19605510 |doi=10.1093/annonc/mdp265 |url=}}</ref>
| |
| |}
| |
|
| |
|
| ==Pathophysiology== | | ==Pathophysiology== |